Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aminopeptidase from Aeromonas proteolytica (AAP) is a prototypical bacterial metalloenzyme that catalyzes the sequential removal of N-terminal amino acids from peptides and proteins. It is notable for containing a dinuclear (two zinc ions) active site with equivalent roles in catalysis, making it a model system for studying co-catalytic mechanisms in metallohydrolases. AAP is a monomeric hydrolase of approximately 29.5 kDa, highly stable under a range of conditions, with broad substrate specificity for hydrophobic N-terminal residues. Its well-characterized structure and mechanism make it important for studies in enzymology, inhibitor design, and as a representative for understanding bacterial aminopeptidases, though it is not itself a direct human drug target.
Inhibitors act by chelating the catalytic zinc ions or by binding to the active site and blocking substrate access.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aminopeptidase from Aeromonas proteolytica (AAP).